Summary
Epilepsy is a common disorder, the prevalence of which is estimated at between 0.1 and 1 % of the population. Although there are a number of medications available for treating the disorder, 20 to 35% of affected individuals are resistant to standard treatments. Many of these patients could benefit from a new anti-epileptic, vigabatrin.
Because the current indication for vigabatrin is as an adjunct in a specific subgroup of epileptic patients, which implies an increased cost of drug therapy, an ex ante economic appraisal of the expected consequences of its introduction in the treatment of epilepsy is valuable. This would provide decision makers with information to complement standard clinical data. Using administrative records of healthcare services utilisation by epileptic patients, we performed a simulation of the expected economic repercussions of vigabatrin use on direct costs related to disease management.
The results show that whether or not the introduction of vigabatrin results in an increase or a reduction in costs to the healthcare system depends largely on 3 factors: (i) the administered dosage of vigabatrin; (ii) the effect that vigabatrin has on hospital admissions; and (iii) the proportion of epileptic patients who take the drug. Moreover, this study underlines the usefulness of administrative data in forecasting the economic impact of new health technologies.
Similar content being viewed by others
References
Griffin J, Wyles M. Epilepsy. London: Office of Health Economics, 1991
Department of Health, Education and Welfare. Plan for nationwide action on epilepsy. Washington, DC: National Institute of Health, 1978. DHEW Publication No. NIH-79-1115
Duncan JS. Modern treatment strategies for patients with epilepsy: a review. J R Soc Med 1991; 84: 159–162
Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41 (6): 889–926
Riekkinen PJ, Pitkanen A, Ylinen A, et al. Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia 1990; 30 Suppl. 3: S18–S22
Brown TR, Mattson TH, Penry JK, et al. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol 1989; 27: 95S–100S
Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991; 6 Suppl. 2: S30–S37
Uldall P, Alving J, Gram L, et al. Vigabatrin in pediatric epilepsy: an open study. J Child Neurol 1991; 6 Suppl. 2: S38–S44
Ben-Menachem E, Malmgren K, Hedstrom A, et al. Efficacy and cost comparison of vigabatrin therapy and epilepsy surgery in patients with intractable complex partial seizures [abstract]. Epilepsia 1993; 34 Suppl. 6: 96
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987: 39–73
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reinharz, D., Kennedy, W., Contandriopoulos, AP. et al. The Economic Effects of Introducing Vigabatrin, a New Antiepileptic Medication. Pharmacoeconomics 8, 400–409 (1995). https://doi.org/10.2165/00019053-199508050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199508050-00004